Form 4: 180 Life Sciences Director Lawrence Steinman Granted Significant Equity Compensation

Lawrence Steinman, a Director at 180 Life Sciences Corp., was granted 48,198 shares of common stock and 110,000 non-qualified stock options as compensation for his services.

Summary

• Lawrence Steinman, a Director of 180 Life Sciences Corp. (ATNF), received equity compensation on June 17, 2025.
• This compensation includes 48,198 shares of common stock and 110,000 non-qualified stock options.
• The common stock was issued at a price of $0.0, and the options have an exercise price of $0.929 per share.
• Both the restricted stock and options vest in two equal tranches: 50% on December 17, 2025, and 50% on June 17, 2026, contingent on continued service.
• The common stock grant was made under the Issuer's 2022 Equity Compensation Plan.
• The non-qualified stock options were granted under the Issuer's 2025 Option Incentive Plan, which requires stockholder approval; options cannot be exercised before approval and will be cancelled if approval is not obtained.
• Following these transactions, Mr. Steinman beneficially owns 115,732 shares of common stock and 110,000 non-qualified stock options.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it indicates a director's continued commitment and alignment with shareholder interests through equity compensation. The only minor caveat is the contingency of option vesting on stockholder approval.

Positives

• The grant of restricted stock and stock options to Director Lawrence Steinman aligns his interests with those of shareholders, incentivizing long-term performance.
• The equity compensation was provided in consideration for services rendered and agreed to be rendered, indicating continued commitment from a key board member.

Negatives

• No explicit negatives are presented in this filing, which primarily reports an equity grant.

Risks

• The 110,000 non-qualified stock options granted under the 2025 Option Incentive Plan are subject to stockholder approval; if approval is not obtained, these options will be cancelled.

Future Outlook

The future outlook for the granted options is contingent on stockholder approval of the 2025 Option Incentive Plan, without which the options will be cancelled. The vesting of both stock and options is also subject to the recipient's continued service to the Issuer through December 2025 and June 2026.

Management Comments

• Represents restricted stock shares subject to time-based vesting, which vest at the rate of 1/2 of such shares on each of December 17, 2025 and June 17, 2026, subject to the recipient's continued service to the Issuer. Issued under the Issuer's 2022 Equity Compensation Plan.
• Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors of the Issuer.
• The options vest 1/2 on each of December 17, 2025 and June 17, 2026, subject to the recipient's continued service to the Issuer. Issued under the Issuer's 2025 Option Incentive Plan. The 2025 Option Incentive Plan is subject to stockholder approval and (i) no options can be exercised prior to obtaining stockholder approval for such plan, and (ii) the outstanding options will be cancelled, if stockholder approval is not obtained.

Industry Context

This Form 4 filing details an equity grant to a director, a common practice across industries to align management and board interests with shareholder value. It does not provide broader industry trends or competitive analysis.

Comparison to Industry Standards

• This document is a specific individual's compensation report and does not contain sufficient information to compare 180 Life Sciences Corp.'s overall financial performance or compensation practices against global benchmarks or specific comparable companies/projects.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of director's interests with shareholder value; however, dilution from new share issuance/option exercise is a consideration.

Next Steps

• Stockholder approval for the 2025 Option Incentive Plan.
• Continued service of Lawrence Steinman to the Issuer for vesting of equity.
• Vesting of restricted stock and options on December 17, 2025, and June 17, 2026.

Key Dates

Keywords

180 Life Sciences Corp., ATNF, SEC Form 4, Beneficial Ownership, Equity Compensation, Stock Options, Restricted Stock, Director Compensation, Lawrence Steinman, Corporate Governance